jeff jacobs photo.jpg

jeffrey jacob

Jeffrey Jacob is currently Chairman of the Board and CEO of Cancer Prevention Pharmaceuticals  He has created several technology-based startup companies and supported the expansion of existing companies in both the physical and life sciences, including Systems Medicine Inc., a startup company applying systems biology, predictive pharmacogenomics, and clinical trial design innovations to the development of new cancer drugs. He was also involved in the founding of the Critical Path Institute and served as a Senior Vice President at Research Corporation Technologies.

 

Peter Hut photo.jpg

peter barton hutt

Peter Barton Hutt is a senior counsel in the Washington, DC law firm of Covington & Burling LLP, specializing in Food and Drug Law. Mr. Hutt is a member of the National Academy of Medicine is a member of the Board of Directors of the Critical Path Institute.  From 1971 to 1975 Mr. Hutt was Chief Counsel for the Food and Drug Administration. During his tenure as FDA Chief Counsel, Mr. Hutt led the transformation of the agency from outdated law enforcement to modern administrative law.

jack dean photo.jpg

jack dean, ph.d.

Dr. Jack Dean retired in January, 2006 as President, U.S. Science and Medical Affairs (R&D), Sanofi- Aventis, Malvern, PA and as the Global Director of Preclinical Development for Sanofi-Aventis, SA (Paris). During his tenure at Sanofi and legacy companies (18 years) he was involved with the registration of twelve NDAs for the US and global market including Plavix, Avapro, Avalide, Ambien CR, and Eloxatin as examples.  He also led the reorganization of global preclinical development through three corporate mergers (Sterling-Winthrop, Synthelabo, and Aventis). 

 

Steve A.jpg

Steve Arneric, ph.d.

Dr. Stephen P. Arneric is a pharmaceutical scientist and leader with a proven track record in delivering differentiated therapeutics. His experience spans more than 25 years of large pharma (Abbott, Lilly, Pharmacia, & Pfizer), biotechnology (DuPont Pharmaceuticals, Neuromed Pharmaceuticals), and academic service (University of Iowa, Cornell Medical College, Southern Illinois University School of Medicine), resulting in over 30 drug candidates entering into clinical development to treat pain and psychiatric and urological disorders. His Launched Product Development experience includes the following: Exalgo™ , Esreboxetine , Dynastat™ , Lyrica™ (neuropathic pain), Cymbalta™ and Detrol™ .